Feras M Hantash

Summary

Affiliation: Quest Diagnostics
Country: USA

Publications

  1. ncbi request reprint Direct visualization of cystic fibrosis transmembrane regulator mutations in the clinical laboratory setting
    Charles M Strom
    Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA, USA
    Clin Chem 50:836-45. 2004
  2. doi request reprint FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency i
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA
    Genet Med 13:39-45. 2011
  3. doi request reprint Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening
    Feras M Hantash
    Department of Molecular Genetics, Nichols Institute, Quest Diagnostics, San Juan Capistrano, California 92690, USA
    Genet Med 12:162-73. 2010
  4. pmc Apparent homozygosity of a novel frame shift mutation in the CFTR gene because of a large deletion
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92690, USA
    J Mol Diagn 11:253-6. 2009
  5. pmc Characterization of a recurrent novel large duplication in the cystic fibrosis transmembrane conductance regulator gene
    Feras M Hantash
    Quest Diagnostics Nichols Institute, Molecular Genetics, 33608 Ortega Hwy, San Juan Capistrano, CA 92690, USA
    J Mol Diagn 9:556-60. 2007
  6. pmc Rapid one-step carrier detection assay of mucolipidosis IV mutations in the Ashkenazi Jewish population
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Incorporated, Nichols Institute, San Juan Capistrano, California 92690, USA
    J Mol Diagn 8:282-7. 2006
  7. ncbi request reprint Novel and recurrent rearrangements in the CFTR gene: clinical and laboratory implications for cystic fibrosis screening
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Hum Genet 119:126-36. 2006
  8. ncbi request reprint Extensive sequencing of the CFTR gene: lessons learned from the first 157 patient samples
    Matthew J McGinniss
    Molecular Genetics Laboratory, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92690 6130, USA
    Hum Genet 118:331-8. 2005
  9. ncbi request reprint A large deletion in the CFTR gene in CBAVD
    Feras M Hantash
    Department of Molecualr Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA
    Genet Med 8:93-5. 2006
  10. ncbi request reprint Development of a novel, accurate, automated, rapid, high-throughput technique suitable for population-based carrier screening for Fragile X syndrome
    Charles M Strom
    Quest Diagnostics, Nichols Institute, San Juan Capistrano, California 92690, USA
    Genet Med 9:199-207. 2007

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Direct visualization of cystic fibrosis transmembrane regulator mutations in the clinical laboratory setting
    Charles M Strom
    Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA, USA
    Clin Chem 50:836-45. 2004
    ..We describe the development and technical validation of a DNA chip in a 96-well format to allow for high-throughput genotype analysis...
  2. doi request reprint FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency i
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA
    Genet Med 13:39-45. 2011
    ..We sought to determine the frequency of fragile X syndrome premutation (55-200 repeats) and full mutation (>200 repeats) alleles in nonselected, unbiased populations undergoing routine carrier screening for other diseases...
  3. doi request reprint Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening
    Feras M Hantash
    Department of Molecular Genetics, Nichols Institute, Quest Diagnostics, San Juan Capistrano, California 92690, USA
    Genet Med 12:162-73. 2010
    ..We describe a triplet-primed polymerase chain reaction-based method using automated capillary electrophoresis detection for qualitative assessment of expanded CGG repeats...
  4. pmc Apparent homozygosity of a novel frame shift mutation in the CFTR gene because of a large deletion
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92690, USA
    J Mol Diagn 11:253-6. 2009
    ..These data highlight the need to prevent misdiagnosis of homozygous mutations, which can lead to misinterpretation of mutation penetrance and its effects on protein function...
  5. pmc Characterization of a recurrent novel large duplication in the cystic fibrosis transmembrane conductance regulator gene
    Feras M Hantash
    Quest Diagnostics Nichols Institute, Molecular Genetics, 33608 Ortega Hwy, San Juan Capistrano, CA 92690, USA
    J Mol Diagn 9:556-60. 2007
    ..The duplication breakpoint is identical in all three patients, suggesting a likely founder mutation...
  6. pmc Rapid one-step carrier detection assay of mucolipidosis IV mutations in the Ashkenazi Jewish population
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Incorporated, Nichols Institute, San Juan Capistrano, California 92690, USA
    J Mol Diagn 8:282-7. 2006
    ..This automated high-throughput assay is labor saving, because two mutations can be detected in a single reaction. The method has potential for use in other assays requiring simultaneous detection of two mutations...
  7. ncbi request reprint Novel and recurrent rearrangements in the CFTR gene: clinical and laboratory implications for cystic fibrosis screening
    Feras M Hantash
    Department of Molecular Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    Hum Genet 119:126-36. 2006
    ..Screening for exon deletions and duplications in the CFTR gene would be beneficial in classic CF cases, especially when only one mutation is identified by standard methodologies...
  8. ncbi request reprint Extensive sequencing of the CFTR gene: lessons learned from the first 157 patient samples
    Matthew J McGinniss
    Molecular Genetics Laboratory, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92690 6130, USA
    Hum Genet 118:331-8. 2005
    ..This enables carrier detection and prenatal diagnosis in additional family members...
  9. ncbi request reprint A large deletion in the CFTR gene in CBAVD
    Feras M Hantash
    Department of Molecualr Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, USA
    Genet Med 8:93-5. 2006
    ..We looked for such mutations in congenital bilateral absence of the vas deferens patients in whom routine screening assays had identified only one or no cystic fibrosis transmembrane regulator gene mutations...
  10. ncbi request reprint Development of a novel, accurate, automated, rapid, high-throughput technique suitable for population-based carrier screening for Fragile X syndrome
    Charles M Strom
    Quest Diagnostics, Nichols Institute, San Juan Capistrano, California 92690, USA
    Genet Med 9:199-207. 2007
    ..To develop a high-throughput, automated, accurate method suitable for population-based carrier detection of fragile X syndrome...
  11. ncbi request reprint Genetically characterized positive control cell lines derived from residual clinical blood samples
    Susan H Bernacki
    Department of Pathology, Duke University Medical Center, Durham, NC, USA
    Clin Chem 51:2013-24. 2005
    ....